Strides Pharma Science Limited Reports Strong Net Profit Growth for Q1 FY27

Strides Pharma Science Limited has released its unaudited financial results for the quarter ended June 30, 2026. The pharmaceutical manufacturer achieved substantial net profit expansion on both a consolidated and standalone basis, buoyed by solid revenue performance and strategic gains.

Consolidated Financial Performance

For the first quarter ending June 30, 2026, Strides Pharma reported consolidated revenue from operations of Rs. 12,654.07 million, reflecting a 13.01% year-over-year growth compared to Rs. 11,197.36 million recorded in the corresponding quarter of the previous year (Q1 FY26). Total consolidated income reached Rs. 12,702.97 million, up from Rs. 11,283.19 million in Q1 FY26.

Consolidated total expenses stood at Rs. 11,325.93 million, compared to Rs. 9,980.08 million in the same period last year. Key expenditure items for the quarter included material costs of Rs. 4,147.15 million, employee benefits expenses of Rs. 2,429.86 million, and other expenses amounting to Rs. 2,974.59 million.

Profit performance showed remarkable momentum:

Profit Before Exceptional Items and Tax: Rs. 1,377.04 million (up from Rs. 1,303.11 million in Q1 FY26).

Exceptional Items: A positive impact of Rs. 631.97 million, compared to an exceptional loss of Rs. 83.67 million in Q1 FY26.

Profit Before Tax: Increased significantly to Rs. 1,996.16 million from Rs. 1,220.43 million in Q1 FY26.

Net Profit for the Period: Rose by 56.73% year-over-year to Rs. 1,654.93 million, compared to Rs. 1,055.93 million reported in June 2025.

Net profit attributable to owners of the company came in at Rs. 1,569.14 million, translating to a Basic and Diluted Earnings Per Share (EPS) of Rs. 17.02 for the quarter (face value Rs. 10 per share), up from Rs. 10.81 in the year-ago period.

Total comprehensive income for the consolidated entity reached Rs. 1,944.10 million after incorporating other comprehensive income of Rs. 289.17 million.

Standalone Financial Results

On a standalone basis, Strides Pharma reported revenue from operations of Rs. 5,826.48 million for the quarter ended June 30, 2026, marking a 16.85% increase from Rs. 4,986.16 million recorded in Q1 FY26. Total standalone income stood at Rs. 5,841.23 million.

Total standalone expenses were managed at Rs. 5,757.66 million, driven mainly by raw material costs of Rs. 3,091.06 million, employee benefit expenses of Rs. 1,024.01 million, and other operating expenses of Rs. 1,148.56 million.

Key highlights of the standalone bottom-line performance include:

Profit Before Exceptional Items and Tax: Rs. 83.57 million.

Exceptional Gains: A substantial gain of Rs. 764.01 million was recorded during the quarter.

Profit Before Tax: Rose to Rs. 847.58 million, up from Rs. 164.03 million in Q1 FY26.

Net Profit for the Period: Surged to Rs. 729.28 million, representing more than a fourfold increase compared to Rs. 133.47 million in the corresponding quarter of the previous year.

Basic and Diluted EPS: Climbed to Rs. 7.91 per equity share, up from Rs. 1.45 in Q1 FY26.

Standalone total comprehensive income stood at Rs. 961.84 million, supported by net other comprehensive income of Rs. 232.56 million.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 1023.25 as compared to the previous close of Rs. 1073.40. The total number of shares traded during the day was 81491 in over 3559 trades.

The stock hit an intraday high of Rs. 1087.00 and intraday low of 1012.65. The net turnover during the day was Rs. 84457445.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate